Clinical trial
Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission
NCT00194519 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00194519 |
|---|---|
| Title | Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission |
| Official title | Phase III Randomized Placebo-Controlled Trial of HSV-2 Suppression to Prevent HIV Transmission Among HIV-Discordant Couples |
| Lead sponsor | University of Washington, Other |
| Collaborators | Bill and Melinda Gates Foundation |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | HIV Infection, Herpes Simplex, Genital, Sexually Transmitted Diseases |
| Intervention type | Drug |
| Interventions | Generic acyclovir, Placebo |
| Enrollment | 3,408 |
| Start date | Nov 1, 2004 |
| Primary completion | Nov 1, 2009 |
| Completion | Mar 1, 2010 |
| First posted | Sep 19, 2005 |
| Last update posted | Oct 12, 2018 |
| Countries | Botswana, Kenya, Rwanda, South Africa, Tanzania, Uganda, Zambia |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: